Amarin 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Amarin Corporation reported total net revenue of $42.2 million in Q2 2026, down from $72.7 million in Q2 2025, which included a $25 million upfront payment from the Recordati transaction.
- Product revenue was $39.1 million in Q2 2026, compared to $46.6 million in Q2 2025, with U.S. product revenue declining to $32.2 million from $36.5 million due to pricing pressure but partially offset by higher volumes.
- European product revenue was $5.4 million in Q2 2026, down from $6.6 million in Q2 2025, reflecting the transition to the Recordati partner model despite a 69% increase in in-market demand.
- Cost of goods sold increased 22% to $27.2 million due to higher product volumes associated with regaining an exclusive PBM relationship in the U.S.
- Total operating expenses declined 59% to $27 million in Q2 2026, excluding restructuring charges, reflecting completed restructuring and a lower cost base.
- Operating loss narrowed to $12 million from $16 million in Q2 2025, a 25% improvement despite higher cost of goods sold.
- Cash and investments increased to $314.6 million at quarter end, with no debt and working capital of $439 million.
- Amarin generated positive cash flow from operations for the third consecutive quarter, $7 million in Q2 2026, and expects positive cash flow for full year 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Morning, and welcome to Amarin Corporation's conference call to discuss its second quarter 2026 financial results. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I would now like to turn the conference call over to Devin Sullivan, investor relations for Amarin.
Thank you for your time and attention this morning as we discuss Amarin's 2026 second quarter financial results. On the call today are Aaron Berg, President and Chief Executive Officer, Steven Ketchum, President, R&D, and Chief Scientific Officer, and Peter Fishman, Chief Financial Officer. Other members of the senior management team will be available as needed during the Q&A session that will follow these prepared comments. Aron will provide a state of the company, Steve will provide an update on recent medical and regulatory activities, and Pete will walk us through the numbers. Before we begin, I'd like to remind everyone that today's press release and related quarterly report on Form 10-Q will be available on the investor relations section of the company's website, www.amarincorp.com, as will a replay of this call shortly after its completion.
Please be aware that during this call, we may make certain statements related to our business that are deemed forward-looking statements under Federal Securities laws. These statements are not guarantees of future performance, but rather are subject to a variety of risks and uncertainties. Our actual results could differ materially from expectations reflected in any forward-looking statements. Additionally, we assume no obligation to update these statements as circumstances change. For a discussion of the material risks and important factors that could affect our actual results, please refer to our SEC filings, which are available either on our company website or the Securities and Exchange Commission's EDGAR system. With that said, I'd now like to turn the call over to Amarin's President and CEO, Aaron Berg. Aron, please go ahead. Thanks, Devin.
Thank you all for joining us today. Q2 2026 marked an inflection point for Amarin, highlighting the one-year anniversary of our dual commercial strategy that combines continued execution of our U.S. business with a fully partnered international commercial platform. The successful implementation of these actions has resulted in a scalable business model while defining a clearer path towards sustainable growth and profitability. We're seeing a promising early-stage international sales trajectory in a number of markets where there remains significant unmet need and long-term potential for VASCEPA while preserving a leading U.S. presence for VASCEPA, supported by a financial foundation that includes a growing cash position and no debt. Our restructuring activities are now complete, resulting in a significantly lower cost base. This refined organizational structure and expense framework will enhance our ability to efficiently execute our long-term growth strategy.
As you may have noticed in our press release, we're now able to provide an outlook for certain key metrics for full year 2026, reflecting the clarity afforded by our new operating model and the strong partnerships that make up its foundation. This underscores how far the business has progressed in the past year while validating our global go-to-market initiatives and reinforcing the continued outstanding execution of our talented, committed team. As of June 30th, 2026, VASCEPA was commercially available in 22 countries via both our fully partnered international commercial strategy and company-managed U.S. presence. Our accelerating international growth is being driven primarily by our exclusive license and supply agreement with Recordati, which covers 59 countries across Europe, as well as our six other commercial partnerships in the rest of the world that cover regions including Canada, China, Israel, the Middle East, Asia, Australia, and New Zealand.
Across this combined global partner network, in-market demand for VASCEPA rose by 59% in cumulative year-over-year volume as of June 30th, compared to the same period last year. As of the end of Q2, VASCEPA is commercialized in 11 countries in Europe, including a recent launch in Romania, and Recordati continues to invest meaningfully with pricing, reimbursement, market access, and adoption advancing in numerous additional countries across the licensed territory. Under Recordati's leadership, VASCEPA is at an early but promising stage of commercialization in Europe's large cardiovascular market, where the disease affects an estimated 62 million people and carries an annual economic burden of approximately EUR 282 billion across the European Union. In-market demand in Europe for VASCEPA under the Recordati partnership rose by 69% in Q2 2026 from Q2 2025.
Spain and the U.K., though early, are leading commercial adoption, providing a strong foundation for future growth as pricing, reimbursement, and commercialization efforts continue across the broader territory. In Italy, where Recordati has one of the country's most established pharmaceutical commercial organizations, VAZKEPA launched with significant commercial support and has demonstrated strong early uptake. VAZKEPA is positioned by Recordati as a priority brand in its cardiovascular portfolio, backed by an expanded cardiovascular commercial infrastructure across Europe, including dedicated field representatives, medical science liaisons, and marketing investment. In its 2025 annual report, Recordati referred to VAZKEPA as a best-in-class treatment option that complements its existing cardiovascular portfolio, is supported by a robust clinical data package, and makes a meaningful impact for cardiovascular patients with residual cardiovascular risk.
While driving utilization in launch markets, Recordati is actively progressing pricing, reimbursement, and market access across additional territories, building a meaningful base for long-term royalty and milestone growth as additional countries come online. While very early, the commercial performance since the June 2025 licensing transaction is encouraging in that Recordati's established cardiovascular infrastructure, broader geographic footprint, and tremendous execution have unlocked substantially greater value from VAZKEPA than would have otherwise been possible had Amarin continued VAZKEPA commercialization throughout Europe alone. The commercial momentum generated by Recordati thus far materially exceeds historical European growth rates achieved by Amarin prior to the licensing transaction. As a reminder, European markets each follow their own regulatory process for pricing, reimbursement, and market access, so commercial launches can progress at different speeds and under varying requirements across countries, despite an overarching EU framework.
In the U.S., our core business continues to serve as a highly efficient, cash-generating base, with VASCEPA retaining a leading position in the icosapent ethyl market despite ongoing generic pressure. We continue to expect to maintain our exclusives with key payers through the end of 2026. The overall U.S. IPE market, based on third-party data, rose by 3% in Q2 2026 compared to Q2 2025. VASCEPA's share of the market rose to 48% as of June 30th, 2026, up from 43% in the same period last year. Despite continued pricing pressure, VASCEPA-branded prescriptions increased 14% year-over-year in the second quarter of 2026, reflecting continued commercial execution in a competitive market. We expect U.S. volumes to remain stable through the end of 2026. Outside of Europe and the U.S., we continue to support our partners in advancing regulatory submissions in various other countries across Asia.
We've recently received approvals in Singapore and South Korea and look forward to the launches in these territories in 2027. As our international footprint continues to expand, the work of our medical affairs, regulatory, and R&D teams becomes increasingly important. Beyond supporting Amarin's own scientific objectives, these teams provide critical expertise to our commercialization partners around the world to contribute to our joint success, helping them navigate local regulatory requirements, continuing to contribute to an already robust library of scientific evidence supporting the benefits and unique attributes of icosapent ethyl, engage with key scientific leaders, support reimbursement discussions, and prepare for successful product launches. Through scientific exchange, congress participation, publication support, medical education initiatives, and ongoing regulatory collaboration, these teams help ensure that our partners have access to the latest data and insights supporting VASCEPA as they work to improve access for patients in their respective markets.
To provide additional perspective on the scientific, medical, and regulatory activities supporting our global growth strategy, I'll now turn the call over to Steven Ketchum.
Steve? Thank you, Aaron. Supporting our global commercialization strategy is an experienced medical affairs, regulatory, technical operations, and R&D organization that works closely with our partners throughout the product life cycle, from regulatory submissions and scientific exchange to market access and commercial launch.
Together, these teams help advance the science behind VASCEPA and VAZKEPA while enabling successful regional commercialization across our global partner network. Our commitment extends well beyond supplying product. We believe sustained scientific leadership is one of the most important ways we create value for patients, healthcare providers, and our partners. More than seven years after the landmark REDUCE-IT results and more than six years after the U.S. approval of VASCEPA for cardiovascular risk reduction, we continue to invest in meaningful scientific research that expands our understanding of cardiovascular risk and reinforces the role of high-dose VASCEPA in contemporary clinical practice.
Beyond generating new evidence, our teams work closely with partners through publication initiatives, scientific congresses, key opinion leader engagement, launch planning, regulatory support, and medical education, helping ensure they are equipped with the latest evidence to support successful commercialization and expand patient access across global markets. That commitment is reflected in a steady cadence of scientific advancements, guideline recognition, and partner-led educational initiatives that continue to strengthen the global evidence base for high-dose VASCEPA icosapent ethyl. In May, we announced new data from a post-hoc analysis of the REDUCE-IT trial that was presented at the European Atherosclerosis Society, or EAS, Congress in Athens, Greece. The analysis, conducted in the REDUCE-IT placebo arm, found that among statin-treated patients with elevated triglycerides, risk-weighted apolipoprotein B, or ApoB, more effectively identified patients who remained at increased residual cardiovascular risk compared with traditional lipid biomarkers.
These recent findings add to the body of evidence that many high-risk patients continue to face substantial residual cardiovascular risk despite statin therapy and highlight the potential value of more refined lipid metrics to better identify patients who may benefit from evidence-based treatment. Prior findings from REDUCE-IT have shown that VASCEPA consistently reduced major adverse cardiovascular event risk across the spectrum of lipoprotein(a) levels, including in patients with elevated lipoprotein(a), an increasingly recognized contributor to residual risk. These previously published findings suggest that any future benefits from emerging lipoprotein(a)-lowering therapies may be complementary to the established cardiovascular risk reduction demonstrated with VASCEPA. This growing body of evidence complements the continued recognition of high-dose icosapent ethyl in leading international treatment guidelines.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
